The Executive Director, AI for Clinical Intelligence and Evidence is a senior enterprise leader responsible for defining how AstraZeneca designs, validates, scales, and externalizes AI-driven evidence capabilities across the full lifecycle of its medicines. This role establishes and leads a critical capability within the AI to Transform Care (AITC) organization, integrating clinical trial data, real-world data, multimodal biomarker inputs, and advanced analytics into continuously learning evidence ecosystems. Beyond traditional evidence generation, this function is accountable for: Designing and governing disease-specific and multimodal foundation models that integrate clinical, molecular, imaging, and real-world data to support continuously learning evidence ecosystems. Defining how these foundation models are validated, regulated, and made HTA- and payer-acceptable. Translating insights into decision-grade evidence that directly informs development strategy, regulatory interactions, medical planning, access positioning, and lifecycle management. Orchestrating AI-driven analytical and agentic workflows that transform integrated data into continuously generated, decision-ready evidence embedded within development, regulatory, and commercial processes. Enabling scalable deployment of AI-enabled evidence capabilities across health systems through strategic partnerships (e.g., EMR-embedded solutions, real-world care networks, and federated data ecosystems). Establishing closed-loop, continuously learning evidence systems that feed real-world outcomes back into development, regulatory, medical, and commercial decision-making. Defining commercialization pathways for AI-enabled evidence assets, including external value creation models aligned with population health and value-based care frameworks. The objective is to transition AstraZeneca from episodic evidence generation to continuously learning, AI-enabled evidence infrastructures that support precision medicine, real-time value demonstration, and sustainable market access. Support all Tier 1 Ph3ID and Tier 1 COMMID’s with RWE and AI packages for development providing +5pp PTS for clinical relevance and +2 months commercial optimization for launches by 2030 Support Key Disease Area Strategies with AI enabled RWE packages Influence semantic layers to reflect strategic vision of AISI & AITC Pioneer AITC, AISI, EDE, Clinical Intelligence and Evidence operating model Overall, this function positions AI-generated evidence and foundation models not as analytical tools, but as strategic enterprise assets, driving differentiation in development, accelerating access, strengthening payer confidence, and enabling scalable transformation of care.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive
Education Level
Ph.D. or professional degree